In the Chinese pharmaceutical industry, there were 34 M&A deals announced in Q3 2024, worth a total value of $4.4bn, according to GlobalData’s Deals Database. The $1.3bn acquisition of Curon Biopharmaceutical by Merck was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
Smarter leaders trust GlobalData
In value terms, M&A activity in China increased by 340% in Q3 2024 compared with the previous quarter’s total of $1bn and rose by 383% as compared to Q3 2023. Related deal volume increased by 100% in Q3 2024 versus the previous quarter and was 6% higher than in Q3 2023.
The top-ranked financial advisors supporting these M&A deals in China in 9M 2024 were BDA Partners; Lazard; CICC Evergreen Fund with 3, 3, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in China in 9M 2024 were Freshfields Bruckhaus Deringer; Bredin Prat & Associates; Clifford Chance with 2, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.
